MONTREAL--(BUSINESS WIRE)--Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today it has appointed David Scheer to its Board of Directors. Mr. Scheer, who is President of Scheer & Company, Inc., a firm focused on life science venture capital, corporate strategy, and transactional advisory services, was involved in the founding and had been a member of the Board of a number of biotechnology companies including, ViroPharma, Inc. (NASDAQ:VPHM), OraPharma, Inc. (acquired by Johnson & Johnson in 2003), and Esperion Therapeutics, Inc. (of which he was Chairman, acquired by Pfizer in 2004).
